Showing 7881-7890 of 10260 results for "".
- Consumer Survey Reveals Widespread Problem of Excessive Sweating and Desire for New Topical Botulinum Toxin Treatmenthttps://practicaldermatology.com/news/20131118-consumer_survey_reveals_widespread_problem_of_excessive_sweating_and_desire_for_new_topical_botulinum_toxin_treatment/2459412/Anterios, Inc announced survey results about current consumer sentiment around exces
- Antares Pharma Enters into Promotion and Marketing Agreement with LEO Pharma for Otrexuphttps://practicaldermatology.com/news/20131118-antares_pharma_enters_into_promotion_and_marketing_agreement_with_leo_pharma_for_otrexup/2459413/Antares Pharma, Inc. announced an exclusive agreement with LEO Pharma for the promotion and marketing of Otrexup (methotrexate) to dermatologists for symptomatic c
- Clinical Significance and Benefit from Scenesse in US Phase III EPP Studyhttps://practicaldermatology.com/news/20131113-clinical_significance_and_benefit_from_scenesse_in_us_phase_iii_epp_study/2459417/A Phase III study (CUV039) evaluating the administration of Scenesse (afamelanotide 16mg) to patients diagnosed with erythropoietic protoporphyria (EPP) has shown a clinically meaningful treatment effect, according to Clinuvel P
- Merz Pharma Group Acquires Anteis S.A.https://practicaldermatology.com/news/20131112-merz_pharma_group_acquires_anteis_sa/2459418/
- FDA Clears Fish-Skin Technology to Heal Human Woundshttps://practicaldermatology.com/news/20131107-fda_clears_fish-skin_technology_to_heal_human_wounds/2459421/Kerecis Limited announced has received FDA 510(k) clearance from the Food and Drug Administration (FDA) to market a proprietary fish-skin, Omega3, tissue-regeneration technology for the treatment of chronic wounds in the US. The technology, marketed under the name MariGen Omega3, is indicated for th
- Pfizer Announces Top-Line Results of Two Phase III Clinical Trials Of Tofacitinibhttps://practicaldermatology.com/news/20131021-pfizer_announces_top-line_results_of_two_phase_iii_clinical_trials_of_tofacitinib/2459433/Pfizer, Inc. recently announced top-line results from two Phase III clinical trials of tofacitinib, a novel, oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chro
- ASDS Elects New Officers, Board Membershttps://practicaldermatology.com/news/20131016-asds_elects_new_officers_board_members/2459435/The American Society for Dermatologic Surgery (ASDS) announces the election of Naomi Lawrence, M.D., as Vice President as well as a new Secretary and three new board members during its Annual Meeting in Chicago. The Society's newly elected officials will join President Mitchel P. Goldman, M.D., and
- Humira Found Effective for Hidradentis Suppurativahttps://practicaldermatology.com/news/20131011-humira_found_effective_for_hidradentis_suppurativa/2459436/Results from a post-hoc analysis of an investigational Phase II study found that Humira (adalimumab, AbbVie) induced significant response rate in adult patients with moderate to severe hidradenitis suppurativa (HS) after 16 weeks of therapy. Researchers used the HS-Physician Global Assessment (HS-P
- FDA Files sBLA for Xolair in Patients with Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20131011-genentech_files_sbla_for_xoliar_in_patients_with_cronic_idiopathic_urticaria/2459437/The FDA accepted and filed Genentech's supplemental Biologics License Application (sBLA) for subcutaneous use of Xolair® (omalizumab) in people with Chronic Idiopathic Urticaria (CIU) who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses. The filing was primarily
- ALPHAEON Acquires Exclusive Worldwide Licensing Rights To TouchMDhttps://practicaldermatology.com/news/20131010-alphaeon_acquires_exclusive_worldwide_licensing_rights_to_touchmd/2459439/ALPHAEON Corp., a leader in lifestyle healthcare and wholly-owned subsidiary of Strathspey Crown Holdings LLC, announced today that it has acquired worldwide licensing rights to TouchMD, for an undisclosed amount. TouchMD is an interactive software platform that helps speciality physicians educate p